- Gilead

Overview

McILVAINE

Q1 2020

Earnings Call Highlights

- **Solid financial performance** delivering product sales of **$5.5 billion** in Q1 2020 with 5% YoY growth
- **Durable core business** driven by HIV franchise delivering **$4.1 billion** in Q1 2020 with 14% YoY growth
- **Biktarvy sales of $1.7 billion** in Q1 2020 with 8% QoQ and 113% YoY growth
- **Progressing pipeline opportunities** including magrolimab and the anticipated launch of filgotinib for RA
- **Forty Seven acquisition** demonstrates our commitment to strategic pipeline buildout
- **Financial and balance sheet strength** supports capital allocation priorities
- **Non-GAAP diluted EPS $1.68**
- **COVID-19 could impact business in the short-term** but we remain confident in long-term outlook of the company
- **Advancing remdesivir as a potential COVID-19 treatment** with unwavering dedication to patients

COVID-19 Macroeconomic Scenarios and Qualitative Implications

WORST CASE

Outbreak continues through YE and slow 2021 recovery blends into a dramatically different "new normal" broadly across global economy

BASE CASE

Epidemiologists forecast peak of pandemic March - July

Potential for COVID return in Fall / Winter but lower impact

Phased return to normal begins in Q2'20 with recovery underway by YE

BEST CASE

Rapid decline in COVID-19 trajectory and accelerated return to normal business conditions in early Q3'20

POTENTIAL **BUSINESS IMPLICATIONS**

- **Strong demand fundamentals** remain relevant and intact
- **Reduced patient visits to HCPs** may affect our business but too early to quantify impact
- **Differential impact across franchises** expected, peaking in Q2'20 with gradual recovery
- **Expect to re-capture majority of any lost revenue** in subsequent time periods, including into 2021
- **Challenge brings opportunity** to support public health response COVID-19
- **Workforce could return** in appropriately phased manner during Q2'20 and Q3'20
- **Paused enrollment for most trials** could lead to lower R&D expense and potentially delayed approvals in long-term
- **Business expected to return to pre-COVID trajectory in Q4'20**

Base case assumptions are drawn from epidemiologists, economists and public health officials.

Remdesivir Overview

- Remdesivir is an investigational, broad-spectrum antiviral invented by Gilead, building on more than a decade of our research
- We have been working rapidly to determine its safety and efficacy as a treatment for COVID-19 and to scale up manufacturing
- Multiple clinical trials are ongoing
- >2,000 patients have received the drug through our compassionate use and expanded access programs
- We have activated expanded access program sites to facilitate emergency use in the U.S. and Europe
- Beyond our 1.5 million dose donation, where authorized by regulatory authorities, Gilead will focus on making remdesivir both accessible and affordable to governments and patients around the world



Our Remdesivir Approach

Establish Safety and Efficacy

Generate clinical data to determine utility and support potential regulatory filings

Scale Up Manufacturing

Expand manufacturing to increase product supply ahead of potential increased demand

Deliver Responsible Access

Provide data-driven access that is ethical for each stage of product development

Common Goal

Determine the safety and efficacy of remdesivir as a treatment for COVID-19 and deliver rapid, broad access for appropriate patients

Overview of Select Remdesivir Studies[1] For the Treatment of COVID-19

Data Source		Target Enrollment	Moderate Hospitalized Patients	Severe Requiring Oxygen	Critical Intubated Patients	Placebo or Standard of Care included?	Key Question	Data Availability – Key Result
REMDESIVIR MONOTHERAPY								
China	Randomized, double-blind	n = 453 237 enrolled	–	✓	–	P	1. Is remdesivir a safe and effective treatment for COVID-19 patients?	Data available – inconclusive Publication in LANCET April 29 Underpowered study; discontinued due to low enrollment
China	Randomized, double-blind	n = 308 74 enrolled	✓	–	–	P		No data available – study suspended Suspended due to low enrollment
NIH NIAID	Randomized, double-blind	n = 1,053	✓	✓	✓	P		Topline: Efficacy Demonstrated Preliminary data in NIH Press Release April 29
GILEAD	Randomized, open label	n = 600[2]	✓	–	–	SoC	2. Is a 5-day treatment course as effective as a 10-day course?	Study in progress Estimated data availability: late May
GILEAD	Randomized, open label	n = 400[3]	–	✓	–	–		Topline: Similar 5-day / 10-day Efficacy Preliminary data in Gilead Press Release April 29
REMDESIVIR COMBINATION THERAPY								
NIH NIAID	Randomized, double-blind combination with Baricitinib	n = TBD	✓	✓	✓	SoC	3. Can combination therapies improve outcomes?	Study to start soon Estimated data: availability TBD

[1] Additional WHO and INSERM studies not shown here. [2] Expansion into Part B with >200 moderate patients enrolled as of April 29. [3] Expansion into Part B with >2700 severe and critical patients enrolled as of April 29.

Safety and Efficacy
Manufacturing
Access

Executive Summary of New Remdesivir Data

NIAID Trial	Gilead SIMPLE Severe Trial
• Study designed to assess safety and efficacy of remdesivir in a broad population of patients hospitalized with COVID-19 • Topline results available based on Data Safety Monitoring Board assessment • Study achieved primary endpoint of shorter time to recover for hospitalized patients treated with remdesivir as compared to placebo (~30% faster overall)	• Study designed to assess 5 days versus 10 days of remdesivir in patients with severe COVID-19 • Results demonstrate similar clinical outcomes with 5 or 10 days of remdesivir • A shorter treatment duration for some will enable more patients to be treated with a limited drug supply

Safety and Efficacy
Manufacturing
Access

Remdesivir Manufacturing Scale-Up

Production is time- and resource-intensive

- Long, linear chemical synthesis that must be completed sequentially
- Involves novel substances, specialized chemistry and sterile drug manufacturing capabilities

Process improvements have shortened the manufacturing timeline

- Timeline is down from 9-12 months to 6-8 months
- Continue to work on optimizing

Additional external manufacturing expands our capacity

- International network essential for raw materials and production capacity
- Consortium of manufacturers in development to coordinate global efforts to increase supply

Current Remdesivir Manufacturing Timeline

Raw Materials
primarily sourced internationally

150 days

(includes time required to produce raw materials)

domestic & international production

Active Pharmaceutical Ingredients

28 days

(typical sterile manufacturing is 60 days)

domestic & international production

Finished Goods



+ Excipient

Unlabeled Drug Product

Testing

Labeling & Packaging

Acceleration Opportunities

- Shorten lead time for raw materials
- Examine new chemistry
- Reduce processing time
- Partner with external parties to supply intermediates

- Onboard additional external manufacturing partners
- Build a consortium of pharmaceutical and chemical manufacturing partners

Remdesivir Manufacturing Projections



Existing supply	+ Existing API, additional Contract Manufacturing Organizations (CMOs), new orders of raw material	+ Additional CMOs and excipient suppliers

[1] Our original supply projections are based on a 10-day treatment course; the number of treatment courses expected to be available may actually be higher based on recent topline results from Gilead's SIMPLE trial in severe patients, which suggests the potential for certain patients to be treated with a shorter dosing duration.
Chart not to scale. A 10-day treatment course involves 11 doses - patients receive two 100mg doses on the first day of treatment and a 100mg dose for each of the remaining 9 days. Figures reflect the cumulative amount of drug that Gilead expects to produce. These projected amounts are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.

Access to Remdesivir

- Where authorized by regulatory authorities, **we will focus on making remdesivir both accessible and affordable to governments and patients around the world**
- We **commit to providing all our current supply of remdesivir at no cost for use in clinical trials, compassionate use and expanded access programs**, and following potential future regulatory authorizations globally
  - This represents 1.5 million individual doses or more than 140,000 treatment courses, assuming a 10-day treatment course
  - We now **anticipate being able to cover significantly more patients, based on the SIMPLE study results in patients with severe disease**
- Pending any regulatory authorizations or approvals, allocation of our existing supply of remdesivir will be made based on **guiding principles that aim to maximize access for appropriate patients in urgent need of treatment**
- Gilead will **continuously evaluate global allocation of supply using multiple, independent data sources** to track the incidence and severity of the outbreak

Total Product Sales

Q1 2020 up 5% from Q1 2019

in millions

By Therapeutic Area



[1] Includes AmBisome, Cayston, Hepsera, Letairis, Ranexa, Vemlidy, Viread and Zydelig.

By Geography

in millions



[2] Q2 2019 product sales include a benefit of ~$160 million (mainly HIV ~$70 million, HCV ~$80 million and HBV ~$10 million) from adjustments for statutory rebates related to Europe sales made in prior years.

COVID-19 Insight: We may see an adverse impact to our HIV, HCV and cell therapy revenues as a result of fewer patient starts beginning in Q2'20. We expect the greatest impact to our HCV and HIV PrEP franchises. Given the current incidence of the pandemic and nature of our business, the impact would be most likely be more pronounced in the U.S. and EU as compared to Asia. To date, the financial impact to our business has been modest.

Durable HIV Franchise Shows Continued and Robust Growth

13% HIV franchise growth since 2011[1]

BIKTARVY®
bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets

Highly effective single tablet regimen for treatment

- **#1 prescribed HIV regimen** and best HIV launch in history[2,3]
- **Expect to be preferred treatment option through 2033**

90-95%
Gilead patients expected on F/TAF-based regimens by Q4'20[4]

Descovy®
emtricitabine 200mg/tenofovir alafenamide 25mg tablets for PrEP pre-exposure prophylaxis

Statistically significant safety improvements for prevention[5]

- **~22%** at-risk individuals on PrEP today[6]
- **~38% PrEP scripts** are for Descovy[7]

40-45%
individuals on PrEP expected to be on Descovy by Q4'20[4]

[1] CAGR Q1 2011 through Q1 2020. [2] Biktarvy #1 prescribed HIV regimen in U.S. in Q1 2020, source Ipsos. [3] Biktarvy best HIV launch in history in U.S. and certain other countries based on prescription volume. [4] Expectations for U.S. patients. [5] Statistically significant advantages with respect to all six pre-specified secondary endpoints for renal and bone laboratory parameters in patients receiving Descovy compared to Truvada. [6] ~1.1m at-risk individuals in U.S., source CDC data; 241k on PrEP, source IQVIA NPA/NSP, SHA Patient Longitudinal Data, Q1 2020. [7] Source: IQVIA NPA/NSP, data are subject to restatement.

Cell Therapy Business Update

YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

- Sales of **$140 million** for Q1 2020 (46% YoY growth and 15% QoQ growth)
- **~2,900 r/r 3L+ large B-cell lymphoma patients** treated with Yescarta
- Amsterdam manufacturing site on track for **end-to-end production in 2020**
- **>176 centers** authorized worldwide
- Expected **2L DLBCL** submission on track for **2021**

KTE-X19

- FDA granted **priority review for KTE-X19** in r/r Mantle Cell Lymphoma
- Expected US approval for MCL on track for H2 2020

COVID-19 Insight: While we do not currently have material supply disruptions, we expect the number of patients treated in Q2'20 to decline as a result of reduced access to authorized treatment centers (ATCs), delayed or cancelled CAR T treatments and the slowing of community referrals to ATCs.

r/r - relapsed refractory. DLBCL - Diffuse large B-cell lymphoma.

Overview of Clinical Pipeline Today



48 Clinical Stage Programs[1]

16 NDA/BLA/MAA, P3 and Registrational P2 trials

16 NMEs via in-licensing, options, and product acquisitions

4 Breakthrough Therapy Designations

[1] Including in-licensing, options, and product acquisitions.

Corporate Development Activities 2019-2020

Guiding Principles for Future Deals

Focus on high quality science that build upon core areas of strength	**Prioritize clinical and commercial opportunities**	**Pursue and execute partnerships** from small to transformative in size and **bolt-on acquisitions** from small to medium in size



News

McILVAINE

Remdesivir

Remdesivir is an experimental medicine that targets genetic material called RNA and is meant to stop SARS-CoV-2 from replicating. Tried previously — without success — as an Ebola drug, it's complex to manufacture and has to be given intravenously.

The U.S. Food and Drug Administration cleared the drug under an emergency authorization on May 1, which will allow hospitalized patients to begin using it. The emergency approval follows early results from a large, placebo-controlled study run by the U.S. government that showed that patients getting remdesivir recovered faster than those that got a placebo. Those findings were at odds with a study out of China out of China that showed remdesivir didn’t help patients get better any faster, and didn’t lower the number of deaths.

McILVAINE

Gilead Discussing Remdesivir Manufacturing with Many Prospective Producers

On May 5 Gilead said it was in discussions with some of the world's leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with several generic drug makers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production. Finally, the company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to license remdesivir for developing countries.

To further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilize their extensive experience providing medicines to low- and middle-income countries during emergency and humanitarian crises to deliver remdesivir using its well-established distribution networks.

Close coordination of remdesivir manufacturing will be critical. This is why Gilead is working to build a consortium of manufacturing partners – to bring efforts together to help maximize global supply. Producing the drug requires scarce raw materials, with their own lengthy production time, and specialized manufacturing capabilities with limited global capacity. Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so.

McILVAINE

Japan Grants Regulatory Approval of Remdesivir

On May 7, 2020 Gilead Sciences, announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted regulatory approval of Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States.

The approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases' global Phase 3 trial, Gilead's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from Gilead's compassionate use program, including patients in Japan.

"The Japanese approval of remdesivir is in recognition of the urgent need to treat critically ill patients in Japan. It is a reflection of the exceptional circumstances of this pandemic," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "We thank the Japanese Ministry of Health, Labor and Welfare for their leadership and collaboration, as we together work to respond to this public health emergency."

McILVAINE

Successful Remdesivir Treatment Reported in mid April at Chicago Hospital

A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead's clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.

The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead's two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.

McILVAINE

Thirty-One Percent Decrease in Hospital Stay for Patients on Remdesivir

The National Institute of Allergy and Infectious Diseases, on April 29 said preliminary data show patients who received remdesivir recovered faster than similar patients who received placebo.

The finding — although difficult to fully characterize without full, detailed data for the study — would represent the first treatment shown to improve outcomes in patients infected with the virus that put the global economy in a standstill and killed at least 218,000 people worldwide.

Anthony Fauci, the director of NIAID, part of the National Institutes of Health, said the data are a “very important proof of concept” and that there was reason for optimism. He cautioned the data were not a “knockout.” At the same time, the study achieved its primary goal, which was to improve the time to recovery, which was reduced by four days for patients on remdesivir.

The preliminary data showed that the time to recovery was 11 days on remdesivir compared to 15 days for placebo, a 31% decrease. The mortality rate for the remdesivir group was 8%, compared to 11.6% for the placebo group; that mortality difference was not statistically significant.

McILVAINE

A Number of Processes Used to Produce Remdesivir

Making an intravenous drug like remdesivir is not a simple process. Filling a vial requires a whole lot of different pieces — many of which are made by other companies — coming together in a final product that has to be pure, sterile, and the same each time. It involves a series of chemical steps that are completed in a particular sequence and ends with a manual inspection of each vial, a process that is "both resource- and time-intensive, with some individual manufacturing steps taking weeks to complete," Gilead wrote in a description of its efforts. Every aspect has to be performed under strict regulatory and safety rules to ensure the drug's standards.

Gilead is also trying to ramp up manufacturing at a time when supply chains for raw materials have been threatened by the very pandemic the drug is trying to combat.

"Most raw materials and most active pharmaceutical ingredients are made in Asia, either in China or India," said Greg Dombal, the president of the life-sciences-focused Halloran Consulting Group. "That supply chain spiders all the way across the world."

Gilead has been preparing. It started building up production when it became clear in the early days of the pandemic that remdesivir might be effective against Covid-19. The company has tapped partners to make the drug as well. It's been procuring raw materials and accelerated the manufacturing process from one that took nine to 12 months to complete to one that takes six to eight months.

McILVAINE

Remdesivir Scale Up with in House And Licensed Manufacture

Remdesivir as a compound is not particularly difficult to synthesize, experts said. But the challenge can be trying to turn on a dime to start making more of it than anticipated.

To some extent, manufacturing facilities can increase the hours that their equipment is running, for example, but there are strict rules for how often those machines have to be cleaned. The compounds have to be regularly assessed and analyzed to make sure they are hitting quality and safety benchmarks.

Scaling up also requires the companies that make all the individual components that go into a final product get on board. That extends from the vial makers to the labeling suppliers to the companies that make “excipients” — the components of a drug beside the active ingredient, which include compounds that help keep it stable or reduce the reactions when the drug is injected.

“It’s not just the company itself that needs to turn it up. It’s forecasting to suppliers and saying, ‘We’re going to have a significant increase in demand here,’” said John Stubenrauch, who has worked in the drug industry for more than two decades and is now senior vice president of operations at Immunomedics.

McILVAINE

More on Scale Up

Big drug makers typically have more than one supplier for those components, Dombal said. But he added, “we build those in for fail safe, not for massive scale up.”

Scaling up quickly can be challenging because such situations will likely require finding other companies with plants that need to be retrofitted, which can be time consuming depending on the technology involved, according to David LaPre, a former Roche executive vice president and head of global pharma technical operations, who oversaw accelerated production of Tamiflu during the Avian flu in 2005.

To supplement what is certain to be worldwide demand, he noted that Gilead may want to consider doing what Roche did, which was to grant licenses to manufacturers in other countries, such as India, in order to supply the lesser-developed parts of the world. This approach, which Gilead has pursued with HIV drugs, took strain off the production system.

“If the stars are aligned you might find one or two plants where the capacity and process capability are a great fit,” LaPre said. “This would be the path of least resistance. A more likely scenario is a number of close fits which require some level of investments

McILVAINE

Gilead Opens New Manufacturing and Packaging Site

In 2017 Gilead Sciences opened a new manufacturing and packaging site in La Verne, Southern California. The new site is set to replace existing operations at the company's facility in San Dimas, California, which manufactures, packages, and labels solid oral dosage form products.

The new campus includes a new 335,000-square-foot facility with an additional 65,000 square feet available for expansion. The site is currently pending US Food and Drug Administration approval of a secondary packaging line for AmBisome (amphotericin B) liposome for injection, Gilead's antifungual drug, as well as continuing equipment validation activities to support further manufacturing and packaging capabilities targeted for regulatory approval in early 2019.

The facility will initially focus on the manufacture of AmBisome. Up to 14 million tablets will be packaged and up to 5 million AmBisome vials will be manufactured per year at the facility. The drug had 2016 sales of $356 million. The facility will also package, label, and distribute more than 20 of the company's products throughout the Americas and the Pacific Rim, including its hepatitis C treatments.

The La Verne site adds to the company's manufacturing and packaging operations. The company has facilities in Foster City, California (process research and development activities, active pharmaceutical ingredient [API] manufacturing for clinical supplies); Oceanside, California (biologics manufacturing for clinical supplies); Edmonton, Alberta, Canada (process research, scale-up, and API manufacturing); and Cork, Ireland (solid-dose tablet manufacturing and packaging)

McILVAINE

Gilead Sciences, Inc. acquired Kite Phara in 2017

Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL).. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma.

"The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. We are greatly impressed with the Kite team and what they have
accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit."

Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California.

McILVAINE

IPRS Repairs Gilead, Cork Cleanroom Panels In Situ

IPRS can carry out repair work while the facility is in operation. For example, it was asked to help with the refurbishment of cleanroom panels during live production at the Gilead Sciences plant in Cork, Ireland.

In this case, damage had been caused during production. A decision was taken to repair all damaged cleanroom cladding in situ, thus preventing the closure of the cleanrooms and preventing a substantial cost for downtime and loss of production.

The quotation for Gilead Sciences was accompanied by an IPRS Safety Statement, a method statement and a risk assessment.

IPRS carried out repair works on both external facade panels and internal cleanroom panels at Gilead and was able to offer a cost-effective alternative to replacing damaged panels by using water-based products, specialized extraction and sterile equipment, without compromising quality, durability or cleanroom efficiency. The company also provides a follow-up service, including personal visits by the contracts manager to assess the completed works.

Established in Ireland in 2002, IPRS has carried out repairs and applied coating systems during construction stage of cleanroom facilities and even during live production in some of the world's leading biopharmaceutical and technology facilities. The company carries out in situ repairs to all coated metal cleanroom ceiling and wall sandwich cladding panels and applies specialised coating systems to damaged areas to avoid creating a habitat that could support a spore outbreak because it cannot be not properly sanitized or sterilized.

McILVAINE

Gilead Expanded in Multiple Countries in the Last Few Years

In 2019 Kite built a 67,000 square-foot facility within its parent company's site in Oceanside, California to ensure sustainable viral vector supply for its cell therapy products.
The Oceanside site will advance viral vector development and supply for both Yescarta (axicabtagene ciloleucel) and its pipeline therapies,.

The facility in Oceanside, CA is dedicated to the manufacturing of viral vectors and will help ensure we have the capabilities to support a robust and sustainable viral vector supply to meet the production needs for cell therapies in the future.

The firm has a 43,500 square-foot plant with the capacity to treat 5,000 patients a year in El Segundo, Santa Monica (also California), that opened in 2016. The firm has also leased a 26,000 square-foot plant in Gaithersburg, Maryland.

Meanwhile in Amsterdam, The Netherlands, Gilead/Kite announced in May 2018 it was opening a 117,000 square-foot facility to support production in Europe.
And iin April 2019, the company announced plans to construct a facility in Frederick County, Maryland expected to begin commercial production by late 2021.
Kite is also leveraging contract manufacturing organizations (CMOs) to supply viral vectors, Salakian said. But as more of its internal network begins operations, Kite will assess its relationship with third-party manufacturers.

McILVAINE

Cleanrooms

McILVAINE

Project Title: Gil**ead**

Revision Date: 12/1/2009
Entry Date: 12/1/2009

Startup Date: 2010
Expansion Date:
Location: OR
City: Seattle / South Lake Union
Size: 106,000 sq. ft. of the facility
Product: Research and development
Address: 199 E. Blaine St.
Telephone:
SIC Description: Research & Development Laboratories
Description:

Updates:

12/1/2008 Gilead, Novo Nordisk Subsidiary Sign Lease Deals within Seattle's South Lake Union:

Project Title: Gilead (bought Pharmasset)

Revision Date: 7/17/2015
Entry Date: 11/25/2013

Startup Date:
Expansion Date: 2015
Location: Canada
City: Edmonton, Alberta
Size: 45,000 sq. ft. expansion
Product: pharmaceuticals
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:

Updates:

7/16/2015: Gilead Sciences Has Opened a New Laboratory
11/25/2013: Gilead to Expand Canadian Plant

Contractors	Contractor Comment
No contactor information available	

Person	Title	Phone	Fax	Email
Robin Nicol	VP and General Manager			

McILVAINE

Project Title: Gilead (bought Pharmasset)

Revision Date: 7/17/2015
Entry Date: 11/25/2013

Startup Date:
Expansion Date: 2015
Location: Canada
City: Edmonton, Alberta
Size: 45,000 sq. ft. expansion
Product: pharmaceuticals
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:

Updates:

7/16/2015: Gilead Sciences Has Opened a New Laboratory
11/25/2013: Gilead to Expand Canadian Plant

McILVAINE

Project Title: Gilead Sciences

Revision Date: 4/15/2015
Entry Date: 4/15/2015

Startup Date: 2015
Expansion Date:

Location: UK
City: Cambridge and Uxbridge
Size:
Product: pharmaceuticals
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:

Updates:

4/15/2015: Gilead to Expand Operations in UK Capital

McILVAINE

Project Title: Gilead Sciences

Revision Date: 5/24/2016
Entry Date: 1/1/2004

Startup Date:
Expansion Date: 2016
Location: CA
City: Foster City and Oceanside
Size: 70,000 sq. ft. facility @4049 Avenida de la Plata
Product: pharmaceuticals and biotechnology
Address: 333 Lakeside Dr., Foster City, CA 94404
Telephone: 650-574-3000 / fax 650-578-9264
SIC Description: Pharmaceuticals
Description:
Gilead Sciences manufactures pharmaceuticals.
Updates:

5/24/2016:	Gilead Plans Expansion at Foster City
7/17/2015:	Gilead is Opening New Labs
5/9/2012:	Science Undergoing Big Building Boom
9/27/2011:	Gilead Sciences Expansion in Foster City
9/27/2011:	Gilead to Purchase Facility from Genentech
12/1/2009:	Gilead Buys Foster City, CA, Building, Land for $137.5 Million from Digital Printing Concern

---

Contractors	Contractor Comment
No contactor information available	

Person	Title	Phone	Fax	Email
John Milligan	President and COO			
Norbert Bischofberger	V.P.			
Robin Nicol	GM			

McILVAINE

Project Title: Gilead Sciences

Revision Date: 11/17/2017
Entry Date: 11/17/2017

Startup Date: 2017
Expansion Date:
Location: CA
City: La Verne
Size: 350,000 sq. ft. facility
Product: pharmaceuticals
Address:
Telephone:
SIC Description: Pharmaceuticals
Description:

Updates:

11/17/2017: Gilead's Facility in La Verne, California

Contractors	Contractor Comment
No contactor information available	

McILVAINE